BackEyePoint Pharmaceuticals Overview

EyePoint Pharmaceuticals Goodwill

Track EyePoint Pharmaceuticals's goodwill ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Goodwill
$0.00

Peer average / median

Loading

EyePoint Pharmaceuticals Goodwill History

Loading

EyePoint Pharmaceuticals vs. peers: Goodwill Comparison

Loading

EyePoint Pharmaceuticals Goodwill Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

EyePoint Pharmaceuticals (EYPT) FAQ

As of the most recent data (June 2026), EYPT shows a goodwill of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EYPT's goodwill is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether EyePoint Pharmaceuticals is outperforming or lagging.

Tracking EYPT's goodwill over time shows whether EyePoint Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this goodwill page, Stockcircle has EyePoint Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect goodwill (currently $0) with ownership activity and broader fundamentals.

EyePoint Pharmaceuticals's goodwill is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.